Results 61 to 70 of about 79,953 (279)
PLoS ONE, 2022 Light chain (AL) amyloidosis is a form of systemic amyloidosis, causing organ dysfunction, mainly affecting the heart and kidney. Patient-tailored and risk-adapted decision making is critical in AL amyloidosis management.
Maria Lourdes Posadas-Martinez +7 more
doaj +1 more source
Extracardiac 18F-florbetapir imaging in patients with systemic amyloidosis: more than hearts and minds [PDF]
, 2018 PURPOSE: 18F-Florbetapir has been reported to show cardiac uptake in patients with systemic light-chain amyloidosis (AL). This study systematically assessed uptake of 18F-florbetapir in patients with proven systemic amyloidosis at sites outside the heart.
Burniston, M +8 more
core +1 more source
Improving management of AL amyloidosis
Annals of the Academy of Medicine, Singapore, 2023 In this issue of the Annals, Tan et al. on behalf of Singapore Myeloma Study Group presented the consensus guidelines on light chain (AL) amyloidosis.1 This is an encouraging effort as AL amyloidosis is a rare disease, with diagnostic and therapeutic challenges.
Yuh Shan, Lee, Jeffrey, Huang
openaire +2 more sources
Annals of Neurology, EarlyView.Objective Quaking‐induced conversion (QuIC) tests, which detect prion‐seeding activity in cerebrospinal fluid (CSF), have markedly advanced the antemortem diagnosis of prion diseases such as Creutzfeldt‐Jakob disease (CJD). These tests provide high diagnostic accuracy and enable timely differentiation from other rapidly progressive neurodegenerative ...
Jennifer Myskiw +13 more
wiley +1 more source
Nuclear Imaging for the Diagnosis of Cardiac Amyloidosis in 2021
Diagnostics, 2021 Cardiac amyloidosis is caused by the deposition of misfolded protein fibrils into the extracellular space of the heart. The diagnosis of cardiac amyloidosis remains challenging because of the heterogeneous manifestations of the disease.
Weijia Li +6 more
doaj +1 more source
Clinical and functional characterisation of a novel TNFRSF1A c.605T > A/V173D cleavage site mutation associated with tumour necrosis factor receptor-associated periodic fever syndrome (TRAPS), cardiovascular complications and excellent response to etanercept treatment. [PDF]
, 2008 Objectives: To study the clinical outcome, treatment response, T-cell subsets and functional consequences of a novel tumour necrosis factor (TNF) receptor type 1 (TNFRSF1A) mutation affecting the receptor cleavage site.
B H Belohradsky +7 more
core +1 more source
Upfront CyBorD in AL amyloidosis [PDF]
Blood, 2015 In this issue of Blood , [Palladini et al][1] report on the outcome of a large series of 230 patients with systemic immunoglobulin (Ig) amyloid light chain (AL) amyloidosis treated frontline with cyclophosphamide, bortezomib, and dexamethasone (CyBorD) at 2 referral centers.[1][2] ![Figure][3]
M Teresa, Cibeira, Joan, Bladé
openaire +2 more sources
Angewandte Chemie International Edition, EarlyView.This study presents the synthesis and binding properties of a new family of o‐terphenyl‐based macrocycles, TP[n] (n = 2‐8). The trimer variant efficiently binds phenylalanine in water with a 10‐fold selectivity compared to other amino acids and aromatic neurotransmitters.
Swapnil Ghule +5 more
wiley +1 more source
Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice [PDF]
, 2009 The SpAs are a group of overlapping, chronic, inflammatory rheumatic diseases including AS, a chronic inflammatory disease primarily affecting the SI joints.
Elewaut, Dirk, Matucci-Cerinic, Marco
core +1 more source
Arthritis &Rheumatology, Accepted Article.Objective High intensity conditioning autologous hematopoietic stem cell transplantation (AHSCT) is standard of care for patients with advanced SSc. The role of reduced intensity conditioning (RIC) prior to AHSCT in this population remains unclear. We conducted this study to determine the long‐term outcomes of RIC AHSCT in SSc patients with cardiac ...
Yonatan Lean +4 more
wiley +1 more source